Table 5: T.SPOT.TB positive versus T.SPOT.TB negative patients. Univariate analyses.

Clinical and laboratory findingsT.SPOT positive ( )T.SPOT negative
( )
value

Age, years, mean ± SD 0.002
Patients with risk factors for LTBI, (%)1 (20)8 (9.2)0.41
SLE disease duration SLE, median (IQR)174 (135–357)126 (60–207)0.10
SLEDAI, mean ± SD 0.43
SLICC, median (IQR)0 (0–0.75)0 (0-1)0.53
dsDNAn, UI/mL, median (IQR) 13.70 (2.05–33)14.50 (3.72–45.50)0.65
Daily prednisone > 7.5 mg, (%)1 (20)17 (19.5)0.53
Immunosuppressed patients, (%)2 (40)57 (65.5)0.56
Hydroxychloroquine treatment, (%)4 (80)75 (86.2)0.54
Steroid dose, mg, mean ± SD 0.67
Steroid cumulative dose, mg, mean ± SD 0.94
Cumulative steroids/duration of disease, mg/year, mean ± SD 0.40
Mycophenolate dose, mg, mean ± SD 0.88
Mycophenolate cumulative dose, mg, mean ± SD 0.001
Cumulative mycophenolate/disease duration, mg/year, mean ± SD 0.001
Methotrexate dose, mg, mean ± SD0 0.38
Methotrexate cumulative dose, mg, mean ± SD 0.77
Cumulative methotrexate/disease duration, mg/year, mean ± SD 0.42